Loading stock data…
Kiniksa Pharmaceuticals Interna (KNSA)
$62.84-0.21 (-0.33%)
Market ClosedLast close Jul 24
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kiniksa Pharmaceuticals International, plc in the Healthcare sector is trading at $62.84 with a market capitalization of $3.7B. Wall Street consensus targets $70.00 (8 analysts), implying a +11.4% move over the next 12 months. The stock is currently near its 52-week high of $67.53, remaining 33.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $214.27M↑ | $202.13M↑ | $180.85M↑ | $156.80M↑ | $137.78M |
| Gross Profit | $117.89M↑ | $111.15M↑ | $97.29M↑ | $85.78M↑ | $76.13M |
| Operating Income | $29.27M↑ | $19.77M↓ | $24.02M↑ | $20.16M↑ | $13.27M |
| Net Income | $22.59M↑ | $14.20M↓ | $18.43M↑ | $17.83M↑ | $8.54M |
Peer Comparison
JNJUNHPFE
Fundamentals
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
52.58
Beta
Defensive asset. Lower volatility than the S&P 500.
0.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.06%
Volume
Today's trading volume
604,888
Recent News
Zacks.com featured highlights include American Outdoor Brands, Cimpress, National Energy Services Reunited, CTO Realty Growth and Kiniksa Pharmaceuticals International
American Outdoor Brands, Cimpress, National Energy, CTO Realty and Kiniksa stand out for recent price strength backed by earnings growth and estimate revisions.
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
5 Stocks With Recent Price Strength Despite Recent Market Volatility
Despite a volatile market, AOUT, CMPR, NESR, CTO and KNSA are five stocks showing recent price strength.
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for a robust portfolio.